GLATTBRUGG, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Cytosurge AG, a biotech company pioneering innovative single-cell biopsies and cell engineering solutions, today announced the open-access publication of its CellEDIT workflow in the peer-reviewed journal . Titled “ ”, the manuscript introduces CellEDIT as a novel approach to cell engineering that leverages intranuclear delivery of CRISPR components to single cells through Cytosurge's proprietary FluidFM OMNIUM Platform technology. The study focuses on Chinese hamster ovary (CHO) cells, widely used in biopharmaceutical production, particularly for monoclonal antibody manufacturing.
However, the non-human glycoprofile of CHO-produced antibodies can affect product quality and therapeutic efficacy, posing challenges to traditional glycoengineering approaches due to their time-consuming and labor-intensive nature. In this proof-of-concept study, Cytosurge's CellEDIT workflow was utilized to engineer CHO cells by delivering CRISPR components simultaneously targeting three genes (BAX, DHFR, and FUT8) directly into single-cell nuclei, resulting in the generation of monoclonal triple knockout CHO-K1 cell lines. Notably, nanoinjection of RNP complexes with FluidFM offered exceptional control over cargo delivery, likely reducing off-target editing and enhancing editing efficiency compared to standard methods.
“In the world of cell engineering, precision is paramount. Our CellEDIT technology, validated in this peer-reviewed.
